Mirum Pharmaceuticals, Inc. (MIRM) Fundamental Analysis: Bull vs. Bear Case

MIRM

Mirum Pharmaceuticals, Inc.

Fundamental data last updated:November 1, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

VALUATION

P/E

-7.34

Market Cap ($M USD)

$5.00B

Forward P/E

11.39 PEG

0.07 PRICE TO SALES

8.78 PRICE TO BOOK

24.17 EV / EBITDA

-130.40

5-Year Average P/E

Free Cash Flow Yield

-3.45%

DCF Value

$-3416.30

Graham Number

N/A

Price to FCF

-28.98

EV to FCF

-28.97

Earnings Yield

-13.63%

FCF Yield

-3.45%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$13.57

Next Year EPS Growth Estimate

$8.75

Next Year Revenue Growth Estimate

$1.73B

Return on Equity (ROE)

-289.33%

FREE CASH FLOW

Operating Margin

-12.31%

Debt-to-Equity

1.02 Piotroski F-Score

3 Altman Z-Score

3.02 Return on Invested Capital (ROIC)

-11.34%

Current Ratio

2.09 Quick Ratio

1.99 Net Debt to EBITDA

0.03 Interest Coverage

-4.87

Gross Profit margin

81.36%

FCF PER SHARE

$-2.93

REVENUE PER SHARE

$9.68

Gainseekers Quantitative Analysis

Summary

Mirum Pharmaceuticals, Inc. appears to be a perplexing enigma in the biotech sector. Despite a staggering market cap, the stock’s valuation is a rollercoaster ride, with a Forward P/E suggesting optimism, yet a negative Earnings Yield and a dismal Altman Z-score indicating financial distress. The market seems to be mispricing it relative to its DCF Value, which is deeply negative, hinting at potential overvaluation. The Graham Number is absent, adding to the uncertainty. While the Forward P/E suggests growth, the company’s safety and financial health are questionable at best.

AI Exposure / Tech Reliance

Operating in the biotechnology industry, Mirum Pharmaceuticals is inherently positioned to leverage advancements in AI and modern technology. The sector's reliance on cutting-edge research and data analytics aligns with AI-driven innovations, potentially enhancing drug discovery and development processes. However, the company's current metrics do not explicitly highlight a strategic focus on tech resilience.

The Bull Case

For the value or GARP investor, Mirum Pharmaceuticals presents an intriguing opportunity. The Forward PEG ratio is exceptionally low, indicating potential undervaluation relative to growth expectations. Despite a negative ROIC, the company's robust Gross Profit Margin suggests pricing power in its niche market. The Piotroski F-Score is modest, but the Current and Quick Ratios indicate liquidity strength, providing a cushion for operational flexibility. These elements could signal a turnaround story in the making.

The Bear Case

Mirum Pharmaceuticals faces significant structural risks that cannot be ignored. The Price/Book and Price/Sales ratios are alarmingly high, suggesting the stock is overvalued relative to its tangible assets and revenue. With a negative FCF Yield and a Price to FCF ratio that screams inefficiency, the company struggles with cash flow generation. Additionally, the stock's proximity to its 52-week high raises concerns about technical overextension, making it a risky bet for cautious investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$142.55

Institutional Ownership %

1-Year Beta

0.52 Insider Buying % (6 Mo)

Distance to 52-Week High

15.45%

Distance to 52-Week Low

56.53%

EARNINGS SURPRISE %

-3,257.50%

50-DAY SMA

$96.89

200-DAY SMA

$84.08

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.